Inside This Issue: Spinocerebellar Ataxias
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Highlights The Neurotech Investing and Partnering Conference 2010
Featured Company: Santhera Pharmaceuticals
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Investors Mull Big Pharma's Future in Neuropsychiatry
A major topic of discussion at NIO and NeuroInsights’ annual Neurotech Investing and Partnering Conference May 19-20 was Big Pharma’s apparent exit from psychiatry R&D. What does this mean for the industry? The pharma focused investors in the “Investing in Neurotech Session” including Art Pappas from Pappas Ventures, Liam Ratcliffe from New Leaf Venture Partners, Raj Shah from RA Capital, and Stephen Knight from Fidelity Bioscience seemed to feel this was an opportunity for smaller companies doing novel research, not to mention some of the niche players focused on CNS like Lundbeck and Biovail...
Companies Pursue New Drugs for Orphan Ataxias with Promise of Premium Pricing
"Ataxia" is often used as a synonym for a specific group of neurodegenerative diseases affecting the sensory and cerebellar pathways that are either hereditary or sporadic. Ataxia may also be used to designate a subset of those diseases when it is an abbreviation for either Ataxia Telangiectasia (Boder-Sedgwick or Louis-Bar syndrome), Friedreich's Ataxia, or Spinocerebellar Ataxia (SCA). Ataxia, as a symptom, may affect anything from delicate finger and hand movements, to coordinated slow eye movements, to gait and balance, to gross body movements and postural reflexes. Also frequently affected is speech, which requires extensive coordination among many small muscles in the larynx, pharynx and tongue and sometimes patients have trouble swallowing. This article outlines types and genetic causes of various ataxias as well as treatments in development ...
Santhera: Adopting Orphan Disorders
Santhera Pharmaceuticals (SWX: SANN) was founded in the summer of 2004 with a focus on orphan neuromuscular diseases. According to Thomas Staffelbach, the head of public and investor relations, Santhera wanted to "replicate what Genzyme did with enzyme replacement for lysosomal storage disorders, but with small molecules for neuromuscular disorders." NeuroInsights spoke with Klaus Schollmeier, who has been the company's CEO since its inception in 2004 and Thomas Meier, CSO about their latest results in Freidriech's Ataxia as well as their recent acquisition of Juvantia....
Companies Covered In This Issue Include: NeuroNova, BrainCells, Signum, Johnson and Johnson, Sepracor, Concentric Meical, QRxPharma, Mylan, Lithera, Newron., Medtronic, St. Jude Medical, Intellipharmaceuticals, MAP Pharmaceuticals, EnVivo, Regeneron, Cadence, Repligen, Ev3, Micrus, Novartis, Vanda, Chelsea, Evbea, Clinical Data, Stem Cell Therapeutics, Genzyme, Alkermes, Biogen Idec, Abbott, Merck, Epicept, Xenoport, GSK, Cyberonics, Sequent Medical, Afraxis, Nupathe, Durin, Axogen, NeuroTherapeutics, Galantos, Greenway , Adeona, Meda, Envoy Medical, IntelGenx, Xanodyne, AgeneBio, Lundbeck, Ipsen, PenWest, Kissei, Shinogi, Takeda, Santhera, ApoPharma
Subscribe Now:
|
|
